Although the FDA approval of lenacapavir as a twice-yearly form of preexposure prophylaxis (PrEP) is “momentous,” cost and access curb excitement, according to Jeremiah Johnson, executive director of ...

The high cost of pharmaceutical products coupled with a lack of federally funded HIV programs create barriers for preexposure prophylaxis (PrEP) access according to Jeremiah Johnson, executive ...

Autoimmune diseases, such as vitiligo, celiac disease and rheumatoid arthritis, are not tied to aluminum exposure from vaccines, according to a nationwide cohort study of approximately 1.2 million ...

In early research, OCU410ST, a gene therapy for Stargardt disease, demonstrated slowed lesion growth by 48% at the 12-month follow-up in evaluable treated eyes.

Switching to extended half-life therapies for hemophilia enhances treatment adherence and reduces infusion frequency, despite ...

The combination of RPI, a genetically engineered herpes simplex virus type 1, and Opdivo shrank both injected and non-injected tumors by 30%.

H. pylori infection significantly contributes to stomach cancer risk, but effective screening and treatment can prevent ...

Alex J. Keoskey is a member of the New Jersey law firm DeCotiis, Fitzpatrick, Cole & Giblin, LLP. Since the beginning of his law career, Mr. Keoskey has been a trial attorney, handling a large variety ...